Enabling equitable open access to commercially funded research publications
Pharmaceutical companies fund much biomedical research, yet many journals restrict open access publishing options for peer-reviewed articles reporting commercially funded research. Expanded publishing options, such as funder-neutral publishing policies, will help address this inequity.
Authors
- Anja Schmidt (ORCID: https://orcid.org/0000-0002-2304-8774)
- Catherine Skobe (ORCID: https://orcid.org/0000-0002-5220-2566)
- Christopher Winchester (ORCID: https://orcid.org/0000-0003-3267-3990)
- Diane R. Stothard
- Eric Topol
Institutions
- Oxford Instruments (United Kingdom) (GB)
- Scripps Research Institute (US)
- Scripps Health (US)
- Eli Lilly (United States) (US)
- Pfizer (United States) (US)
- Takeda (United States) (US)
- Scripps Clinic (US)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2026-08-27
- DOI
- https://doi.org/10.1371/journal.pmed.1005207
- Primary Topic
- Academic Publishing and Open Access
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer